TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANDOVER, Mass., Feb. 3, 2025 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on January 28, 2025, TransMedics granted non-qualified stock options to purchase an aggregate of 34,884 shares of its common stock and an aggregate of 23,192 restricted stock units to 3 employees, each as a material inducement for each employee's entry into employment with TransMedics. The grants were approved by the Compensation Committee of the TransMedics Board of Directors and were granted in accordance with Nasdaq Listing Rule 5635(c)(4) and pursuant to the TransMedics Group, Inc. Inducement Plan.